- Home
- CURI vs CERS Comparison
CURI vs CERS Comparison
Compare CURI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- CERS
- Stock Information
- Founded
- CURI N/A
- CERS 1991
- Country
- CURI United States
- CERS United States
- Employees
- CURI N/A
- CERS N/A
- Industry
- CURI Movies/Entertainment
- CERS EDP Services
- Sector
- CURI Consumer Discretionary
- CERS Technology
- Exchange
- CURI Nasdaq
- CERS Nasdaq
- Market Cap
- CURI 264.7M
- CERS 276.0M
- IPO Year
- CURI N/A
- CERS 1997
- Fundamental
- Price
- CURI $4.88
- CERS $1.55
- Analyst Decision
- CURI Strong Buy
- CERS Strong Buy
- Analyst Count
- CURI 3
- CERS 2
- Target Price
- CURI $6.00
- CERS $3.50
- AVG Volume (30 Days)
- CURI 521.1K
- CERS 1.6M
- Earning Date
- CURI 11-05-2025
- CERS 10-29-2025
- Dividend Yield
- CURI 6.64%
- CERS N/A
- EPS Growth
- CURI N/A
- CERS N/A
- EPS
- CURI N/A
- CERS N/A
- Revenue
- CURI $60,840,000.00
- CERS $192,510,000.00
- Revenue This Year
- CURI $36.83
- CERS $19.07
- Revenue Next Year
- CURI $9.44
- CERS $12.03
- P/E Ratio
- CURI N/A
- CERS N/A
- Revenue Growth
- CURI 11.02
- CERS 13.25
- 52 Week Low
- CURI $1.47
- CERS $1.12
- 52 Week High
- CURI $7.15
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- CURI 47.23
- CERS 54.88
- Support Level
- CURI $4.68
- CERS $1.52
- Resistance Level
- CURI $5.38
- CERS $1.70
- Average True Range (ATR)
- CURI 0.28
- CERS 0.09
- MACD
- CURI -0.07
- CERS -0.01
- Stochastic Oscillator
- CURI 25.58
- CERS 46.30
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.